Shopping Cart 0
Cart Subtotal
USD 0

GC Pharma (006280) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

GC Pharma(GC Pharma) formerly known as Green Cross Corp, a subsidiary of Green Cross Holdings Corp provides plasma protein therapeutics and vaccines. The company develops, manufactures and markets a wide product portfolio comprising plasma derivatives including albumin, immunoglobulin, and antithrombin; vaccines for infectious diseases; prescription drugs for treating cardiovascular, respiratory, central nervous system (CNS), gastrointestinal and immunology diseases, musculoskeletal disorders, genetic disorders, metabolic disorders and hematological disorders; and Over-the-counter (OTC) drugs including anti-inflammatory drugs, anti-allergic products and others. The company focuses its research and development activities at developing pharmaceuticals for difficult to treat diseases, including cancer. GC Pharma is headquartered Yongin-si, Gyeonggi-do, South Korea.

GC Pharma (006280)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GC Pharma, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

GC Pharma, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GC Pharma, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

GC Pharma, Medical Devices Deals, 2012 to YTD 2018 10

GC Pharma, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

GC Pharma, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Argos Therapeutics Raises USD 60 Million In Series E Financing 13

Partnerships 16

Yuhan to Enter into Agreement with GC Pharma 16

Feldan Therapeutics and Green Cross LabCell Enter into Research Partnership 17

AroCell Enters into Co-Development Agreement with Green Cross Cell 18

Green Cross Cell Forms Joint Venture with Harbin Hou pu Tong tang Biotech 19

Green Cross Cell and ToolGen to Enter into Partnership 20

OGD2 Pharma Enters into Agreement with Green Cross LabCell 21

Oxford BioMedica Enters into Agreement with Green Cross 22

Green Cross Enters into Commercialization Agreement with Nanolek 23

Aquavit Pharma Announces Co-Development Agreement With Green Cross For IBX-001 24

Licensing Agreements 25

Lee's Pharma Enters into Licensing Agreement with GC Pharma 25

Green Cross Enters into Licensing Agreement with Argos Therapeutics 26

Equity Offering 28

Green Cross LabCell Prices IPO of Shares for USD32 Million 28

Innocell Completes Private Placement Of Shares For USD 13 Million 29

Debt Offering 30

Green Cross Cell Raises USD55.3 Million in Private Placement of Convertible Bonds 30

Acquisition 31

Green Cross Acquires Additional 7.07% Stake In Ildong Pharma From WhanIn Pharma 31

GC Pharma-Key Competitors 32

GC Pharma-Key Employees 33

GC Pharma-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Recent Developments 36

Strategy And Business Planning 36

May 20, 2018: GC Pharma to Establish Curevo-a Seattle-based New Company Dedicated to Development of New Vaccines 36

Apr 29, 2017: Green Cross to Build Cell Therapy Manufacturing Facility in China 37

Financial Announcements 38

Oct 30, 2018: GC Pharma reports Q3 2018 results 38

Jul 31, 2018: GC Pharma Reports Q2 2018 Results 39

Apr 27, 2018: GC Pharma Announces Q1 2018 Results 40

Feb 05, 2018: GC Pharma Reports Full Year 2017 Results 41

Product News 42

01/18/2018: GC Pharma Confirms Phase 2/3 Clinical Trial of New Protein Therapy for Hepatitis B 42

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43


List Of Figure

List of Figures

GC Pharma, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

GC Pharma, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

GC Pharma, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GC Pharma, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

GC Pharma, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GC Pharma, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

GC Pharma, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

GC Pharma, Pharmaceuticals & Healthcare, Key Facts, 2017 2

GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GC Pharma, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

GC Pharma, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GC Pharma, Deals By Therapy Area, 2012 to YTD 2018 9

GC Pharma, Medical Devices Deals, 2012 to YTD 2018 10

GC Pharma, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Argos Therapeutics Raises USD 60 Million In Series E Financing 13

Yuhan to Enter into Agreement with GC Pharma 16

Feldan Therapeutics and Green Cross LabCell Enter into Research Partnership 17

AroCell Enters into Co-Development Agreement with Green Cross Cell 18

Green Cross Cell Forms Joint Venture with Harbin Hou pu Tong tang Biotech 19

Green Cross Cell and ToolGen to Enter into Partnership 20

OGD2 Pharma Enters into Agreement with Green Cross LabCell 21

Oxford BioMedica Enters into Agreement with Green Cross 22

Green Cross Enters into Commercialization Agreement with Nanolek 23

Aquavit Pharma Announces Co-Development Agreement With Green Cross For IBX-001 24

Lee's Pharma Enters into Licensing Agreement with GC Pharma 25

Green Cross Enters into Licensing Agreement with Argos Therapeutics 26

Green Cross LabCell Prices IPO of Shares for USD32 Million 28

Innocell Completes Private Placement Of Shares For USD 13 Million 29

Green Cross Cell Raises USD55.3 Million in Private Placement of Convertible Bonds 30

Green Cross Acquires Additional 7.07% Stake In Ildong Pharma From WhanIn Pharma 31

GC Pharma, Key Competitors 32

GC Pharma, Key Employees 33

GC Pharma, Other Locations 34

GC Pharma, Subsidiaries 34

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

GC Pharma, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

GC Pharma(GC Pharma) formerly known as Green Cross Corp, a subsidiary of Green Cross Holdings Corp provides plasma protein therapeutics and vaccines. The company develops, manufactures and markets a wide product portfolio comprising plasma derivatives including albumin, immunoglobulin, and antithrombin; vaccines for infectious diseases; prescription drugs for treating cardiovascular, respiratory, central nervous system (CNS), gastrointestinal and immunology diseases, musculoskeletal disorders, genetic disorders, metabolic disorders and hematological disorders; and Over-the-counter (OTC) drugs including anti-inflammatory drugs, anti-allergic products and others. The company focuses its research and development activities at developing pharmaceuticals for difficult to treat diseases, including cancer. GC Pharma is headquartered Yongin-si, Gyeonggi-do, South Korea.

GC Pharma (006280)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GC Pharma, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

GC Pharma, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GC Pharma, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

GC Pharma, Medical Devices Deals, 2012 to YTD 2018 10

GC Pharma, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

GC Pharma, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Argos Therapeutics Raises USD 60 Million In Series E Financing 13

Partnerships 16

Yuhan to Enter into Agreement with GC Pharma 16

Feldan Therapeutics and Green Cross LabCell Enter into Research Partnership 17

AroCell Enters into Co-Development Agreement with Green Cross Cell 18

Green Cross Cell Forms Joint Venture with Harbin Hou pu Tong tang Biotech 19

Green Cross Cell and ToolGen to Enter into Partnership 20

OGD2 Pharma Enters into Agreement with Green Cross LabCell 21

Oxford BioMedica Enters into Agreement with Green Cross 22

Green Cross Enters into Commercialization Agreement with Nanolek 23

Aquavit Pharma Announces Co-Development Agreement With Green Cross For IBX-001 24

Licensing Agreements 25

Lee's Pharma Enters into Licensing Agreement with GC Pharma 25

Green Cross Enters into Licensing Agreement with Argos Therapeutics 26

Equity Offering 28

Green Cross LabCell Prices IPO of Shares for USD32 Million 28

Innocell Completes Private Placement Of Shares For USD 13 Million 29

Debt Offering 30

Green Cross Cell Raises USD55.3 Million in Private Placement of Convertible Bonds 30

Acquisition 31

Green Cross Acquires Additional 7.07% Stake In Ildong Pharma From WhanIn Pharma 31

GC Pharma-Key Competitors 32

GC Pharma-Key Employees 33

GC Pharma-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Recent Developments 36

Strategy And Business Planning 36

May 20, 2018: GC Pharma to Establish Curevo-a Seattle-based New Company Dedicated to Development of New Vaccines 36

Apr 29, 2017: Green Cross to Build Cell Therapy Manufacturing Facility in China 37

Financial Announcements 38

Oct 30, 2018: GC Pharma reports Q3 2018 results 38

Jul 31, 2018: GC Pharma Reports Q2 2018 Results 39

Apr 27, 2018: GC Pharma Announces Q1 2018 Results 40

Feb 05, 2018: GC Pharma Reports Full Year 2017 Results 41

Product News 42

01/18/2018: GC Pharma Confirms Phase 2/3 Clinical Trial of New Protein Therapy for Hepatitis B 42

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43


List Of Figure

List of Figures

GC Pharma, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

GC Pharma, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

GC Pharma, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GC Pharma, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

GC Pharma, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GC Pharma, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

GC Pharma, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

GC Pharma, Pharmaceuticals & Healthcare, Key Facts, 2017 2

GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GC Pharma, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

GC Pharma, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GC Pharma, Deals By Therapy Area, 2012 to YTD 2018 9

GC Pharma, Medical Devices Deals, 2012 to YTD 2018 10

GC Pharma, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Argos Therapeutics Raises USD 60 Million In Series E Financing 13

Yuhan to Enter into Agreement with GC Pharma 16

Feldan Therapeutics and Green Cross LabCell Enter into Research Partnership 17

AroCell Enters into Co-Development Agreement with Green Cross Cell 18

Green Cross Cell Forms Joint Venture with Harbin Hou pu Tong tang Biotech 19

Green Cross Cell and ToolGen to Enter into Partnership 20

OGD2 Pharma Enters into Agreement with Green Cross LabCell 21

Oxford BioMedica Enters into Agreement with Green Cross 22

Green Cross Enters into Commercialization Agreement with Nanolek 23

Aquavit Pharma Announces Co-Development Agreement With Green Cross For IBX-001 24

Lee's Pharma Enters into Licensing Agreement with GC Pharma 25

Green Cross Enters into Licensing Agreement with Argos Therapeutics 26

Green Cross LabCell Prices IPO of Shares for USD32 Million 28

Innocell Completes Private Placement Of Shares For USD 13 Million 29

Green Cross Cell Raises USD55.3 Million in Private Placement of Convertible Bonds 30

Green Cross Acquires Additional 7.07% Stake In Ildong Pharma From WhanIn Pharma 31

GC Pharma, Key Competitors 32

GC Pharma, Key Employees 33

GC Pharma, Other Locations 34

GC Pharma, Subsidiaries 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

GC Pharma, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.